Pluristem therapeutics inc (PSTI)
Income statement / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10
Revenues

54

50

-

2,847

379

379

679

716

0

0

Cost of revenues

2

2

-

100

13

11

20

21

0

-

Gross profit

52

48

-

2,747

366

368

659

695

0

-

Research and development expenses

29,882

26,371

24,001

22,856

23,416

24,938

19,906

12,685

8,311

6,123

Less: participation by the Israeli Innovation Authority (IIA), Horizon 2020 and other parties

3,455

3,742

2,909

3,276

4,243

5,396

2,673

3,527

-

-

Less participation by the Office of the Chief Scientist and other parties

-

-

-

-

-

-

-

-

-1,682

-1,822

Research and development expenses, net

26,427

22,629

21,092

19,580

19,173

19,542

17,233

9,158

6,629

4,301

General and administrative expenses, net

9,157

11,193

6,927

6,486

6,460

8,676

5,649

6,568

4,485

3,138

Other income

-

43

-

0

-

-

-

-

-

-

Operating loss

-35,532

-33,731

-28,019

-23,319

-25,267

-27,850

-22,223

-15,031

-11,114

-7,439

Financial income (expense), net

225

7,605

205

73

590

918

1,068

237

-

-

Financial income, net

-

-

-

-

-

-

-

-

266

-14

Net loss for the period

-35,307

-26,126

-27,814

-23,246

-24,677

-26,932

-21,155

-14,794

-10,848

-7,453

Basic and diluted net loss per share (in Dollars per share)

-2.90

-2.50

-3.20

-0.29

-0.35

-0.42

-0.38

-0.34

-0.35

-0.44

Weighted average number of shares used in computing basic and diluted net loss per share (in Shares)

12,332

10,587

8,742

79,547

70,284

63,514

55,481

44,031

-

-

Weighted average number of shares used in computing basic and diluted net loss per share

-

-

-

-

-

-

-

-

31,198

17,004